[
  {
    "ts": null,
    "headline": "Amgen (AMGN) Advances While Market Declines: Some Information for Investors",
    "summary": "Amgen (AMGN) closed at $260.64 in the latest trading session, marking a +0.52% move from the prior day.",
    "url": "https://finnhub.io/api/news?id=849a4fd3f9782f0f5f294c6764beacb06d3a08d56bfd6a608228e169366bfe2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735685418,
      "headline": "Amgen (AMGN) Advances While Market Declines: Some Information for Investors",
      "id": 132222137,
      "image": "https://media.zenfs.com/en/zacks.com/4f1a8d86cead9f96536efb147945dcc9",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) closed at $260.64 in the latest trading session, marking a +0.52% move from the prior day.",
      "url": "https://finnhub.io/api/news?id=849a4fd3f9782f0f5f294c6764beacb06d3a08d56bfd6a608228e169366bfe2c"
    }
  },
  {
    "ts": null,
    "headline": "GLP-1 questions emerge for 2025",
    "summary": "The 2025 outlook for GLP-1s isn't as bullish as it once was, but all hope is not lost.",
    "url": "https://finnhub.io/api/news?id=10d16fd7419a29a826adae343cff42b8cce630ca6029cd6b54f4057e9d8f8745",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735681738,
      "headline": "GLP-1 questions emerge for 2025",
      "id": 132221988,
      "image": "https://s.yimg.com/ny/api/res/1.2/o.xKVkL_2cKm_990lun34w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2023-12/2d578f90-9d7d-11ee-bd6d-e9421ec244af",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The 2025 outlook for GLP-1s isn't as bullish as it once was, but all hope is not lost.",
      "url": "https://finnhub.io/api/news?id=10d16fd7419a29a826adae343cff42b8cce630ca6029cd6b54f4057e9d8f8745"
    }
  },
  {
    "ts": null,
    "headline": "Akero Therapeutics: Where This Potential MASH Play Stands Currently",
    "summary": "Discover the latest on Akero Therapeutics, Inc., a biotech firm focusing on metabolic balance therapies, with a market cap of $2 billion. Click for my AKRO update.",
    "url": "https://finnhub.io/api/news?id=59f1490761432441566bcb1c76e1b8ca8e84060130f68c53918f19c2e06d32c5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735649392,
      "headline": "Akero Therapeutics: Where This Potential MASH Play Stands Currently",
      "id": 132216255,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184964962/image_184964962.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Discover the latest on Akero Therapeutics, Inc., a biotech firm focusing on metabolic balance therapies, with a market cap of $2 billion. Click for my AKRO update.",
      "url": "https://finnhub.io/api/news?id=59f1490761432441566bcb1c76e1b8ca8e84060130f68c53918f19c2e06d32c5"
    }
  },
  {
    "ts": null,
    "headline": "This Biotech Is One of the S&P 500’s Worst Performers. It Looks Too Cheap.",
    "summary": "This Biotech Is One of the S&P 500’s Worst Performers. It Looks Too Cheap.",
    "url": "https://finnhub.io/api/news?id=372459c0450a0a8c44bad940edc33a0deb4f95ee859cf2bb4a3316f84f8972be",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735603260,
      "headline": "This Biotech Is One of the S&P 500’s Worst Performers. It Looks Too Cheap.",
      "id": 132324426,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "This Biotech Is One of the S&P 500’s Worst Performers. It Looks Too Cheap.",
      "url": "https://finnhub.io/api/news?id=372459c0450a0a8c44bad940edc33a0deb4f95ee859cf2bb4a3316f84f8972be"
    }
  }
]